newsfilter
← Latest News
GlobeNewswire·

SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update

First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical hold, triggering a $10M milestone payment from GSK. An additional $20M milestone will be triggered upon the six month anniversary